---
title: "Moleculin Biotech (MBRX.US) — Financial Reports"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/MBRX.US/norm.md"
symbol: "MBRX.US"
name: "Moleculin Biotech"
parent: "https://longbridge.com/en/quote/MBRX.US.md"
datetime: "2026-05-19T17:19:21.442Z"
locales:
  - [en](https://longbridge.com/en/quote/MBRX.US/norm.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/MBRX.US/norm.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/MBRX.US/norm.md)
---

# Moleculin Biotech (MBRX.US) — Financial Reports

## Income Statement (USD)

| Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| EPS | -3.54 | 6.90 | -17.02 | -27.28 | -17.22 |
| ROE | -387.16% | -1037.30% | 596.13% | 1940.42% | -855.14% |
| Revenue | - | - | - | - | - |
| Net income | -14.61M | 15.45M | -25.40M | -17.28M | -6.44M |
| Operating income | -7.87M | -7.53M | -5.91M | -5.72M | -5.94M |
| Gross margin | - | - | - | - | - |
| Net margin | - | - | - | - | - |
| Profit quality | - | - | - | - | - |

## Balance Sheet (USD)

| Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| A&L | 23.36M | 22.13M | 20.35M | 21.59M | 21.01M |
| Leverage | 1.54 | 1.47 | -0.7561 | -3.01 | 500.31 |
| BVPS | 2.85 | 4.69 | -13.60 | -5.93 | 0.0743 |
| Turnover | - | - | - | - | - |
| Cash & STI | 10.32M | 8.88M | 6.70M | 7.56M | 7.72M |
| Inv & Rec | - | - | - | - | - |
| LT assets | 354000.00 | 392000.00 | 420000.00 | 469000.00 | 525000.00 |
| Net debt | -10.13M | -8.52M | -6.31M | -7.14M | -7.27M |

## Cash Flow Statement (USD)

| Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| Operating CF | -6.11M | -5.37M | -7.22M | -5.58M | -4.56M |
| Investing CF | - | - | - | - | - |
| Financing CF | 7.61M | 7.49M | 6.38M | 5.42M | 8.00M |
| Free CF | -3.50M | -2.61M | -5.26M | -2.01M | -2.37M |
| OCF coverage | - | - | - | - | - |
| Repaid & issued | - | - | - | - | - |
| CapEx | - | - | - | - | - |